| 季杰,朱迪,谢玉官,王福安,吕朋华,周卫忠,闫乐乐.TACE联合阿帕替尼及卡瑞利珠单抗治疗巨块型肝细胞癌[J].中国介入影像与治疗学,2025,22(5):310-314 |
| TACE联合阿帕替尼及卡瑞利珠单抗治疗巨块型肝细胞癌 |
| TACE and apatinib combined with camrelizumab for treating giant hepatocellular carcinoma |
| 投稿时间：2025-02-22 修订日期：2025-04-30 |
| DOI：10.13929/j.issn.1672-8475.2025.05.002 |
| 中文关键词: 癌，肝细胞 肿瘤负荷 化学栓塞，治疗性 抗肿瘤药 治疗结果 |
| 英文关键词:carcinoma,hepatocellular tumor burden chemoembolization,therapeutic antineoplastic agents treatment outcome |
| 基金项目: |
|
| 摘要点击次数: 64 |
| 全文下载次数: 30 |
| 中文摘要: |
| 目的 观察TACE联合阿帕替尼及卡瑞利珠单抗治疗巨块型肝细胞癌（HCC）的疗效及安全性。方法 回顾性纳入78例巨块型HCC，其中22例接受TACE联合阿帕替尼及卡瑞利珠单抗治疗（TACE+AC组）、56例接受TACE联合阿帕替尼治疗（TACE+A组），通过倾向性匹配以1∶2比例在TACE+A组中确定44例与TACE+AC组相匹配，以之为TACE+A＇组；记录各组总生存期（OS）、无进展生存期（PFS）及药物相关不良反应并进行比较。结果 TACE+AC组中位OS为17.8（95%CI：17.5～18.1个月、中位PFS为8.8（95%CI：5.4～12.3）个月，TACE+A＇组分别为9.8（95%CI：7.6～12.1）个月及5.5（95%CI：2.7～8.3）个月；TACE+AC组总体OS率及总体PFS率均高于TACE+A＇组（P均＜0.05）。TACE+AC组甲状腺功能异常、免疫性肺炎及反应性毛细血管增生症的发生率高于TACE+A＇组（P均＜0.05）。各组均无不良反应相关性死亡。结论 相比TACE联合阿帕替尼，进一步联合卡瑞利珠单抗治疗巨块型HCC可带来更多生存获益且不良反应可控。 |
| 英文摘要: |
| Objective To explore the efficacy and safety of TACE and apatinib combined with camrelizumab for treating giant hepatocellular carcinoma （HCC）. Methods Totally 78 patients with giant HCC were retrospectively collected， including 22 cases received TACE and apatinib combined with camrelizumab （TACE+AC group） and 56 cases received TACE and apatinib（TACE+A group）. Propensity score matching analysis was used to select 44 cases （TACE+A＇ group） from TACE+A group who were matched to those in TACE+AC group at 1∶2 ratio. The overall survival（OS）， progression-free survival （PFS） and the adverse events were recorded and compared among groups. Results Patients in TACE+AC group had a median OS of 17.8 （95%CI： 17.5—18.1） months and a median PFS of 8.8 （95%CI： 5.4—12.3） months， which in TACE +A＇group was 9.8 （95%CI： 7.6—12.1） months and 5.5 （95%CI： 2.7—8.3） months， respectively. The overall OS rate and PFS rate in TACE+AC group were significantly higher than those in TACE+A＇ group （both P＜0.05）. The incidences of thyroid dysfunction， immune pneumonia and reactive cutaneous capillary endothelial proliferation in TACE+AC group were significantly higher than those in TACE+A＇ group （all P＜0.05）. No death associated with adverse events occurred. Conclusion Compared with TACE and apatinib， further combining with camrelizumab could get better survival benefit for giant HCC patients with acceptable adverse events. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
